
Twenty patients with progressive zzso solid zzso were entered into a study to evaluate the biological effects and toxicity of zzso human zzso zzso factor zzso zzso was given as half-hour intravenous infusions during two 10-day zzso of daily treatments zzso by 10 days without zzso and over a final phase of 20 days of alternate day zzso zzso were escalated in steps from zzso to 60 zzso zzso zzso between successive patient zzso zzso increases zzso less than zzso of total zzso zzso and zzso zzso counts were seen over the periods of daily infusions (up to zzso rises of total white zzso at dose levels of 10 zzso zzso and zzso zzso produced at 30 zzso zzso were significantly higher than at 10 zzso zzso zzso less than zzso zzso side effects of zzso included mild transient zzso bone pain and zzso The maximum tolerated dose was 60 zzso zzso which produced severe toxicity in zzso of zzso The toxicity at this dose included zzso and zzso ascribed to a zzso zzso One patient receiving 60 zzso zzso died as a result of a pulmonary zzso Seven patients with previously rapidly progressive zzso zzso experienced zzso of disease while receiving zzso and one patient with a previously heavily zzso zzso soft tissue zzso underwent a greater than 50% reduction of zzso zzso Patients undergoing chemotherapy may benefit both from a reduction of the zzso effects of zzso agents and from an zzso effect if zzso is incorporated into future zzso 

